RxDoctor Payments Data

Seda Badalyan, MD

Internal Medicine · la Jolla, CANPI 1558396077

Payments from drug & device makers

$5,131in general payments, 2019–2025

Across 234 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$712
  • AbbVie$398
  • Novo Nordisk$398
  • Pfizer$371
  • Amgen$364
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$5,08199%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,131 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$134,591
Medicare patients
300
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide159$210,794
EliquisApixaban60$79,807
JardianceEmpagliflozin58$68,442
FarxigaDapagliflozin Propanediol41$51,456
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$28,857
MyrbetriqMirabegron27$26,706
MounjaroTirzepatide15$19,717
LinzessLinaclotide14$14,249
Advair HfaFluticasone Propion/Salmeterol22$10,129
Estradiol85$5,973
Potassium Chloride24$3,702
Levothyroxine Sodium307$3,699
Rosuvastatin Calcium226$3,263
Estradiol (Twice Weekly)Estradiol26$3,003
Duloxetine Hcl69$2,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$398$210,794159 claims
PfizerEliquis$371$79,80760 claims
Boehringer IngelheimJardiance$24$68,44258 claims
AstraZenecaFarxiga$1,140$51,45641 claims
GSKTrelegy Ellipta$313$28,85727 claims
Astellas Pharma US IncMyrbetriq$113$26,70627 claims
Lilly USA, LLCMounjaro$712$19,71715 claims
AbbVieLinzess, Synthroid$398$14,87836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →